News

Oncolytics Biotech's Strategic Engagement at Upcoming Conferences

Oncolytics Biotech's Strategic Engagement at Upcoming Conferences

Oncolytics Biotech Takes Center Stage at Investment Conferences

Oncolytics Biotech Inc. (NASDAQ: ONCY), a prominent clinical-stage biotechnology firm, has announced its participation in key investment conferences aimed at highlighting advancements in cancer immunotherapy. The company is committed to pioneering innovative treatments and continues to play a crucial role in the battle against various cancer types.

Fireside Chats Scheduled with Key Leaders

Kirk Look, the Chief Financial Officer, is set to participate in an engaging fireside chat at the well-regarded H.C. Wainwright 26th Annual Global Investment Conference. This event will take place at the Lotte New York Palace Hotel and will serve as a valuable platform for discussing Oncolytics' strategic initiatives in oncology.

Details of the H.C. Wainwright Conference

The conference is scheduled for September 11, with Kirk Look's presentation slated for 9:00 a.m. ET. Attendees can look forward to gaining in-depth insights into Oncolytics’ direction and performance in the immuno-oncology arena.

Participation at the Cantor Global Healthcare Conference

Additionally, Oncolytics' Chief Medical Officer, Tom Heineman, M.D., Ph.D., will be sharing his expertise during a fireside chat at the Cantor 2024 Global Healthcare Conference on September 19. This session will provide investors and stakeholders with valuable insights into the therapeutic potential of pelareorep, Oncolytics’ groundbreaking immunotherapeutic agent.

Highlights of the Cantor Conference

Tom Heineman is scheduled to present at 10:55 a.m. ET at the InterContinental New York Barclay Hotel, focusing on how pelareorep is revolutionizing treatment methods in oncology.

One-on-One Investor Meetings to Enhance Engagement

Alongside group discussions, the management team will facilitate one-on-one meetings with investors throughout the conferences. Stakeholders are encouraged to request these meetings via the conference platforms or by contacting their respective representatives directly.

About Pelareorep and Oncolytics’ Clinical Trials

Oncolytics Biotech is leading the development of pelareorep, an intravenously administered agent that has demonstrated significant promise in treating metastatic breast cancer and pancreatic cancer. By stimulating immune system responses, pelareorep uniquely transforms “cold” tumors into “hot” tumors, making them more responsive to various cancer therapies.

Current clinical trials suggest that pelareorep can enhance the effectiveness of existing oncology treatments. Oncolytics is making diligent progress towards registrational studies for both metastatic breast cancer and pancreatic cancer, which have received Fast Track designation from the FDA. This designation highlights the urgency and potential impact of their research findings.

Connect with Oncolytics Biotech

For more information about Oncolytics Biotech Inc. and its innovative approaches in oncology, visit their official website or follow their updates on social media platforms.

Frequently Asked Questions

What is Oncolytics Biotech known for?

Oncolytics Biotech Inc. is recognized for its innovative immunotherapeutic agent, pelareorep, which is being developed to treat various cancer types.

When are the upcoming investment conferences?

The H.C. Wainwright Annual Conference is set for September 11, and the Cantor Global Healthcare Conference will occur on September 19.

Who will represent Oncolytics at the conferences?

Kirk Look and Tom Heineman will represent Oncolytics during their respective fireside chats at the conferences.

How can investors schedule one-on-one meetings?

Investors can arrange one-on-one meetings through the conference websites or by reaching out to their representatives.

What advancements has pelareorep shown in clinical trials?

Pelareorep has demonstrated promising results in triggering anti-cancer immune responses and improving treatment effectiveness for metastatic breast cancer and pancreatic cancer.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Biointron's RushDATA™: Speeding Up Antibody Discovery

Updated Category News Views 207

A New Chapter in Antibody Discovery Well, color me intrigued. Biointron, a name you'd recognize if you've got even a toe in the biotech pond, just threw a serious curveball into the antibody discovery game with RushDATA™—an AI- and machine learning-driven platform that's packing a punch. And it's not just about throwing tech buzzwords around; this thing clocks...

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 157

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
When to Switch Your LLC to S Corp Status: Tips

Updated Category News Views 79

Is Your LLC Ready for the S Corp Leap? Thinking about shifting your LLC to S corporation status? You're not alone—many business owners hit this fork in the road as their enterprise starts rolling in more dough. And if you're scratching your head wondering if this switch makes sense for your venture, listen up because timing and context are everything here. When Should...

Continue Reading
Will Hair Loss Drugs Challenge Transplant Clinics?

Updated Category News Views 73

Emerging Treatments Stir Up Hair Loss Scene You ever get the feeling we're on the brink of something big? That's where we are with hair loss treatments, folks. As of late 2026, new drugs are making waves in clinical trials, but they’re not yet giving hair transplant clinics any sleepless nights. Smile Hair Clinic's co-founders, Dr. Mehmet Erdo?an and Dr. Gökay Bilgin,...

Continue Reading
SPOC Energy's Hiring Push Signals Growth Surge

Updated Category News Views 64

A Growing Workforce for a Growing Demand Here we are, smack dab in a bustling week of business news, and among it, SPOC Energy is ramping up its workforce across Alabama. Now, SPOC isn't any run-of-the-mill operation; this Birmingham-based manufacturer messes around with advanced power conversion systems and motor-control automation—a mouthful, sure, but critical stuff...

Continue Reading
Foreigner to Rock Irvine with Night Ranger in 2027

Updated Category News Views 85

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Continue Reading
Philip Scroggie's Legacy in Global Energy Projects

Updated Category News Views 116

A Lifetime of Energy Industry Excellence When you've been around the block in the energy sector as long as Philip D. Scroggie has, you're bound to pick up a few accolades. Recognized as an Inner Circle Lifetime Member, this guy has etched his name in the annals of global energy project management. Yeah, he's been a heavyweight in the oil, gas, and LNG industries, and he's...

Continue Reading
TruGreen Finds New Growth in Birch Hill Acquisition

Updated Category News Views 204

TruGreen's New Chapter Begins In the world of lawn care, TruGreen is sowing the seeds for a revitalized future, courtesy of its recent acquisition by Birch Hill Equity Partners. Based out of Franklin, Tennessee, this powerhouse in the green arena is set to start a fresh chapter, swapping partners like old gloves after a long, 19-year stint with Clayton, Dubilier & Rice...

Continue Reading
The Melt Expands with Key Texas Franchise Deal

Updated Category News Views 130

Throwing Down the Gauntlet: The Melt Expands If there's one thing I've learned after decades watching these restaurant chains multiply like rabbits it’s this: when a veteran gets involved, you perk up. The Melt has done just that by roping in Syed Ahmad—a name that actually means something in this game—to open eight new locations in the Lone Star State. It isn't...

Continue Reading
ADI Global Faces Investor Investigation Over Major Write-Down

Updated Category News Views 60

Towering Goodwill Falls and Investor Scrutiny Well, let's dig into this mess ADI Global Distribution has found itself in. If you were hanging onto ADIG shares, your portfolio probably took quite the hit when they revealed a nasty $659 million goodwill write-down. Imagine opening up those financials and seeing about 62% of goodwill value wiped out overnight. Suddenly, that...

Continue Reading

Top 5 Most Recently Viewed Articles

Arvinas Reflects on Successful Year, Projecting Future Growth

Updated Category News Views 220

Arvinas' Notable Advances in 2024 Arvinas, Inc. (Nasdaq: ARVN), a pioneering clinical-stage biotechnology company, continues on its ambitious path, showing significant progress in 2024. The company has been steadfast in its mission to develop innovative therapies targeting debilitating diseases through its unique PROTAC platform. Their latest advancements signal a...

Continue Reading
Understanding NB Private Equity Partners and Their Recent Buyback

Updated Category News Views 256

NB Private Equity Partners Publishes Share Buyback Details Today, NB Private Equity Partners, commonly referred to as NBPE, has made significant strides to enhance its shareholders' value through a recent buyback of its Class A shares. This transaction, carried out in accordance with the general authority bestowed upon the company’s management by shareholders, showcases...

Continue Reading
China’s AI Innovations Enhance Global Development Efforts

Updated Category News Views 385

China’s Commitment to AI Development In recent years, China has made significant strides in artificial intelligence (AI) development, showcasing its dedication to fostering technological innovation and bolstering cooperation with nations around the world. One of the central aspects of this commitment was highlighted during a recent inspection tour by Chinese President...

Continue Reading
Exploring Crypto-Bound Stocks: A Guide to Peak Investments

Updated Category News Views 209

Bitcoin and Ethereum Driving Market Momentum Recently, Bitcoin experienced a significant breakout, surpassing its previous all-time high of around $112,000 and hitting new heights above $123,000. Although it has cooled off somewhat, it remains consolidated just above its previous resistance level, which now functions as a key support zone. With Bitcoin's year-to-date...

Continue Reading
Verra Mobility's Plunge: A 45% Stock Drop Shakes Investors

Updated Category News Views 147

Surprise Hit: Verra Mobility Takes a Blow Verra Mobility's situation feels like having a rug yanked out from under one's feet. The company sent its shareholders into a tailspin after disclosing a major hit: losing a contract with Avis, which accounted for more than 10% of its annual revenue. We're talking about a stock that nosedived roughly 45%—it's the kind of...

Continue Reading